Manpreet K Singh1, Andrei Pikalov2, Cynthia Siu3, Michael Tocco2, Antony Loebel2. 1. Psychiatry and Behavioral Sciences, Stanford University, Stanford, California, USA. 2. Sunovion Pharmaceuticals, Inc., Marlborough, Massachusetts, and Fort Lee, New Jersey, USA. 3. COS and Associates Ltd., Central, Hong Kong, People's Republic of China.
Abstract
Objectives: To evaluate the efficacy and safety of lurasidone in the treatment of children and adolescents with bipolar depression presenting with mixed (subsyndromal hypomanic) features. Methods: Patients, 10-17 years of age, with a Diagnostic and Statistical Manual of Mental Disorders, 5th ed. (DSM-5), diagnosis of bipolar I depression were randomized to 6 weeks of double-blind treatment with once-daily flexible doses of lurasidone 20-80 mg or placebo. The presence of mixed (subsyndromal hypomanic) features in this pediatric bipolar depression trial was defined as a Young Mania Rating Scale score of 5 or greater at study baseline. Key efficacy measures included change from baseline to week 6 in the Children's Depression Rating Scale-Revised (CDRS-R) score (primary endpoint) and Clinical Global Impressions-Bipolar Severity (CGI-BP-S) score, using a mixed model for repeated measures analysis. Results: At baseline, subsyndromal hypomanic features were present in 54.2% of patients. Treatment with lurasidone (vs. placebo) was associated with significantly greater reductions in CDRS-R scores at week 6, independent of the presence (-21.5 vs. -15.9, p < 0.01; effect size d = 0.43) or absence (-20.5 vs. -14.9, p < 0.01; d = 0.44) of subsyndromal hypomanic features. Likewise, lurasidone (vs. placebo) was associated with significantly greater reductions in CGI-BP-S scores at week 6, independent of the presence (-1.6 vs. -1.1, p < 0.001, d = 0.51) or absence (-1.3 vs. -1.0, p = 0.05; d = 0.31) of these subsyndromal hypomanic features. Rates of protocol-defined treatment-emergent hypomania or mania were similar for lurasidone and placebo in patients with (lurasidone 8.2% vs. placebo 9.0%) or without subsyndromal hypomanic features (lurasidone 1.3% vs. placebo 3.7%). Conclusions: In this post hoc analysis of a randomized placebo-controlled trial, lurasidone was found to be efficacious in the treatment of child and adolescent patients with bipolar depression who presented with mixed (subsyndromal hypomanic) features. No differences in safety profile, including the risk of treatment-emergent mania, were observed in patients with or without subsyndromal hypomanic features in this study.
RCT Entities:
Objectives: To evaluate the efficacy and safety of lurasidone in the treatment of children and adolescents with bipolar depression presenting with mixed (subsyndromal hypomanic) features. Methods:Patients, 10-17 years of age, with a Diagnostic and Statistical Manual of Mental Disorders, 5th ed. (DSM-5), diagnosis of bipolar I depression were randomized to 6 weeks of double-blind treatment with once-daily flexible doses of lurasidone 20-80 mg or placebo. The presence of mixed (subsyndromal hypomanic) features in this pediatric bipolar depression trial was defined as a Young Mania Rating Scale score of 5 or greater at study baseline. Key efficacy measures included change from baseline to week 6 in the Children's Depression Rating Scale-Revised (CDRS-R) score (primary endpoint) and Clinical Global Impressions-Bipolar Severity (CGI-BP-S) score, using a mixed model for repeated measures analysis. Results: At baseline, subsyndromal hypomanic features were present in 54.2% of patients. Treatment with lurasidone (vs. placebo) was associated with significantly greater reductions in CDRS-R scores at week 6, independent of the presence (-21.5 vs. -15.9, p < 0.01; effect size d = 0.43) or absence (-20.5 vs. -14.9, p < 0.01; d = 0.44) of subsyndromal hypomanic features. Likewise, lurasidone (vs. placebo) was associated with significantly greater reductions in CGI-BP-S scores at week 6, independent of the presence (-1.6 vs. -1.1, p < 0.001, d = 0.51) or absence (-1.3 vs. -1.0, p = 0.05; d = 0.31) of these subsyndromal hypomanic features. Rates of protocol-defined treatment-emergent hypomania or mania were similar for lurasidone and placebo in patients with (lurasidone 8.2% vs. placebo 9.0%) or without subsyndromal hypomanic features (lurasidone 1.3% vs. placebo 3.7%). Conclusions: In this post hoc analysis of a randomized placebo-controlled trial, lurasidone was found to be efficacious in the treatment of child and adolescent patients with bipolar depression who presented with mixed (subsyndromal hypomanic) features. No differences in safety profile, including the risk of treatment-emergent mania, were observed in patients with or without subsyndromal hypomanic features in this study.
Entities:
Keywords:
bipolar depression; children and adolescents; lurasidone; mixed (subsyndromal hypomanic) features
Authors: Antony Loebel; Josephine Cucchiaro; Robert Silva; Hans Kroger; Kaushik Sarma; Jane Xu; Joseph R Calabrese Journal: Am J Psychiatry Date: 2014-02 Impact factor: 18.112
Authors: R J Baldessarini; L Bolzani; N Cruz; P B Jones; M Lai; B Lepri; J Perez; P Salvatore; M Tohen; L Tondo; E Vieta Journal: J Affect Disord Date: 2009-06-28 Impact factor: 4.839
Authors: R L Findling; B L Gracious; N K McNamara; E A Youngstrom; C A Demeter; L A Branicky; J R Calabrese Journal: Bipolar Disord Date: 2001-08 Impact factor: 6.744
Authors: Alessandro Cuomo; Viktoriya L Nikolova; Nefize Yalin; Danilo Arnone; Andrea Fagiolini; Allan H Young Journal: CNS Spectr Date: 2017-04-18 Impact factor: 3.790
Authors: Anna R Van Meter; Coty Burke; Robert A Kowatch; Robert L Findling; Eric A Youngstrom Journal: Bipolar Disord Date: 2016-01-09 Impact factor: 6.744
Authors: Mark A Frye; Gerhard Helleman; Susan L McElroy; Lori L Altshuler; David O Black; Paul E Keck; Willem A Nolen; Ralph Kupka; Gabriele S Leverich; Heinz Grunze; Jim Mintz; Robert M Post; Trisha Suppes Journal: Am J Psychiatry Date: 2008-11-17 Impact factor: 18.112